Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This phase 3 study will serve to collect efficacy and safety data of two different doses of
NT 201 in subjects suffering from Bilateral Blepharospasm (BEB) who are BTX treatment-naïve.
In this study, BTX treatment-naïve subjects are defined as those who have not received BTX
treatment within the last 12 months for the treatment of BEB. This definition aims to avoid
bias by comparison of treatment effects in the subject's assessments. Furthermore, this study
will substantiate the existing efficacy and safety database for the indication BEB.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA